Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib Combined with Immunotherapy and Local Therapy for Pre-treated Unresectable Hepatocellular Carcinoma
NCT06496815Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Aug 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of donafenib in hepatocellular carcinoma (HCC), sponsored by Tongji Hospital. Primary endpoints: Objective Response Rate at 1 year and Progression-Free Survival at 1 year. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
donafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06496815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06496815.